Abstract
BackgroundJanus Kinase inhibitors (JAKi) are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) used in the treatment of inflammatory arthritis. Whilst evidence for their efficacy and side-effect profile is supported by...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
